FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde.
During the last decade, a new view into the molecular mechanisms of chronic kidney disease-mineral bone disorder (CKD-MBD) has been proposed, with fibroblast growth factor 23 (FGF23) as a novel player in the field. Enhanced serum FGF23 levels cause a reduction in serum phosphate, together with calcitriol suppression and consequent hyperparathyroidism (HPT). In contrast, reduced serum FGF23 levels are associated with hyperphosphatemia, higher calcitriol levels and parathyroid hormone (PTH) suppression. In addition, serum FGF23 levels are greatly increased and positively correlated with serum phosphate levels in CKD patients. In this population, high serum FGF23 concentration seems to predict the occurrence of refractory secondary HPT and to be associated with higher mortality risk in incident haemodialysis patients. In living-donor kidney transplant recipients, a faster normalization of FGF23 and phosphate levels with a lower prevalence of HPT, may be considered a major pathway to investigate.
Nephrology Dialysis and Renal Transplant Unit, S. Orsola Hospital, Department of Experimental Diagnostic and Specialty Medicine (DIMES) , University of Bologna , Bologna , Italy.
Giuseppe
G
Cianciolo
Renal Unit, San Paolo Hospital Milan, Department of Health and Science , University of Milan , Milan , Italy.
Mario
M
Cozzolino
CKD-MBD; FGF23; PTH; secondary hyperparathyroidism
N Engl J Med. 1999 Dec 2;341(23):1725-30
10580071
Kidney Int. 2001 Jun;59(6):2377-87
11380848
J Am Soc Nephrol. 2002 Feb;13(2):551-8
11805187
Am J Kidney Dis. 2004 Aug;44(2):250-6
15264182
Kidney Int. 2005 Jan;67(1):341-8
15610260
Curr Opin Nephrol Hypertens. 2006 Mar;15(2):97-104
16481873
Am J Transplant. 2007 May;7(5):1193-200
17359508
J Am Soc Nephrol. 2007 Sep;18(9):2600-8
17656479
N Engl J Med. 2008 Aug 7;359(6):584-92
18687639
Clin J Am Soc Nephrol. 2008 Nov;3(6):1829-36
18922992
Clin J Am Soc Nephrol. 2009 Mar;4(3):685-90
19211668
Circulation. 2009 May 19;119(19):2545-52
19414634
Atherosclerosis. 2009 Dec;207(2):546-51
19524924
Am J Transplant. 2009 Nov;9(11):2470-8
19681815
J Bone Miner Res. 2010 Oct;25(10):2091-7
20593414
Nephrol Dial Transplant. 2011 Aug;26(8):2691-5
21303965
Kidney Int. 2011 Jun;79(12):1370-8
21389978
J Am Soc Nephrol. 2011 May;22(5):956-66
21436289
Am J Transplant. 2011 Oct;11(10):2093-109
21883901
J Clin Invest. 2011 Nov;121(11):4393-408
21985788
Clin J Am Soc Nephrol. 2012 Feb;7(2):323-31
22134626
J Nephrol. 2012 Nov-Dec;25(6):1108-18
22383345
Am J Kidney Dis. 2013 Feb;61(2):310-25
23102732
Nephrol Dial Transplant. 2012 Nov;27(11):4227-35
23144073
Am J Transplant. 2013 Jan;13 Suppl 1:11-46
23237695
Clin J Am Soc Nephrol. 2013 Nov;8(11):1968-78
23929933
Am J Transplant. 2013 Oct;13(10):2653-63
24034142
PLoS Genet. 2013;9(12):e1003975
24348262
Semin Nephrol. 2014 Mar;34(2):151-63
24780470
Transplantation. 2016 Jan;100(1):184-93
26177089
Nephrol Dial Transplant. 2016 Jul;31(7):1088-99
26681731
J Clin Invest. 2016 Mar 1;126(3):962-74
26878171
Am J Nephrol. 2016;43(6):397-407
27229347
Clin Kidney J. 2016 Oct;9(5):669-76
27679713
J Clin Invest. 1995 Dec;96(6):2809-19
8675651